- Home
- MDCX vs ATNM Comparison
MDCX vs ATNM Comparison
Compare MDCX & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- ATNM
- Stock Information
- Founded
- MDCX 2008
- ATNM 2000
- Country
- MDCX Canada
- ATNM United States
- Employees
- MDCX N/A
- ATNM N/A
- Industry
- MDCX
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- ATNM Health Care
- Exchange
- MDCX Nasdaq
- ATNM Nasdaq
- Market Cap
- MDCX 44.0M
- ATNM 51.5M
- IPO Year
- MDCX N/A
- ATNM N/A
- Fundamental
- Price
- MDCX $3.10
- ATNM $1.52
- Analyst Decision
- MDCX Strong Buy
- ATNM Strong Buy
- Analyst Count
- MDCX 2
- ATNM 3
- Target Price
- MDCX $23.50
- ATNM $4.67
- AVG Volume (30 Days)
- MDCX 482.2K
- ATNM 492.9K
- Earning Date
- MDCX 08-22-2025
- ATNM 08-04-2025
- Dividend Yield
- MDCX N/A
- ATNM N/A
- EPS Growth
- MDCX N/A
- ATNM N/A
- EPS
- MDCX N/A
- ATNM N/A
- Revenue
- MDCX N/A
- ATNM N/A
- Revenue This Year
- MDCX N/A
- ATNM N/A
- Revenue Next Year
- MDCX N/A
- ATNM N/A
- P/E Ratio
- MDCX N/A
- ATNM N/A
- Revenue Growth
- MDCX N/A
- ATNM N/A
- 52 Week Low
- MDCX $1.80
- ATNM $1.03
- 52 Week High
- MDCX $8.94
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- ATNM 51.90
- Support Level
- MDCX N/A
- ATNM $1.41
- Resistance Level
- MDCX N/A
- ATNM $1.49
- Average True Range (ATR)
- MDCX 0.00
- ATNM 0.11
- MACD
- MDCX 0.00
- ATNM 0.00
- Stochastic Oscillator
- MDCX 0.00
- ATNM 58.33
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.